Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Removab 10micrograms/0.1ml concentrate for inf pfs
0801050BFBBABAB
|
Removab | Catumaxomab | Malignant Disease and Immunosuppression | No data available |
|
Removab 50micrograms/0.5 concentrate for inf pfs
0801050BFBBAAAA
|
Removab | Catumaxomab | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 15mg capsules
0802040Y0BBACAC
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 2.5mg capsules
0802040Y0BBAEAE
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 20mg capsules
0802040Y0BBAGAG
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 25mg capsules
0802040Y0BBADAD
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 5mg capsules
0802040Y0BBAAAA
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Revlimid 7.5mg capsules
0802040Y0BBAFAF
|
Revlimid | Lenalidomide | Malignant Disease and Immunosuppression | No data available |
|
Rezurock 200mg tablets
0802040BEBBAAAA
|
Rezurock | Belumosudil | Malignant Disease and Immunosuppression | No data available |
|
Rituximab 1.4g/11.7ml solution for injection vials
0802030F0AAACAC
|
Rituximab | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Rituximab 500mg/50ml solution for infusion vials
0802030F0AAAAAA
|
Rituximab | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Rixathon 100mg/10ml concentrate for inf vials
0802030F0BDAAAB
|
Rixathon | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Rixathon 500mg/50ml concentrate for inf vials
0802030F0BDABAA
|
Rixathon | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 18million units/0.5ml inj pre-filled syringes
0802040J0BCAQBG
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 18million units/0.6ml inj cartridges
0802040J0BCAPBF
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 3million units/0.5ml inj pre-filled syringes
0802040J0BCAJAV
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 4.5million units/0.5ml inj pre-filled syringes
0802040J0BCAKAW
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 6million units/0.5ml inj pre-filled syringes
0802040J0BCALAX
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Roferon-A 9million units/0.5ml inj pre-filled syringes
0802040J0BCAMAY
|
Roferon-A | Interferon alpha | Malignant Disease and Immunosuppression | No data available |
|
Ropeginterferon alfa-2b 250microg/0.5ml inj pf dispos dev
0802040BCAAAAAA
|
Ropeginterferon A | Ropeginterferon alfa | Malignant Disease and Immunosuppression | No data available |
|
Ruxience 100mg/10ml concentrate for inf vials
0802030F0BEACAB
|
Ruxience | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Ruxience 500mg/50ml concentrate for inf vials
0802030F0BEABAA
|
Ruxience | Rituximab | Malignant Disease and Immunosuppression | No data available |
|
Ruxolitinib 10mg tablets
0801050BIAAADAD
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Ruxolitinib 20mg tablets
0801050BIAAACAC
|
Ruxolitinib | Ruxolitinib | Malignant Disease and Immunosuppression | No data available |
|
Rydapt 25mg capsules
0801050CKBBAAAA
|
Rydapt | Midostaurin | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.